Exosect Appoints New Chairman and Financial Director

David Richardson is the new financial director, while Peter Keen is the new chairman.

February 15, 2011

WINCHESTER, UK — Exosect announced two new appointments.  David Richardson joins Exosect as financial director. With more than 20 years financial experience, a qualified accountant and treasurer, Richardson’s experience has been focused in the bio-technology sector working for companies such as Evotec AG, Zeneca Cellmark Diagnostics and Marlow Foods then part of ICI Biological Products.

Peter Keen was recently appointed as Exosect’s new non-executive chairman. Keen is a chartered accountant and brings with him over 25 years experience in financing and management of companies within the emerging bio-technology and pharmaceuticals sectors.

Keen is currently a non executive director of Ark Therapeutics Groups PLC, Biotechnology Growth Trust plc (“BGT) and Abcam plc which he joined prior to the companies’ IPO. He is also the Non Executive Director of Serentis Ltd.  Previously he was the CFO at Arakis until its successful trade sale in 2005.
 

Related